Atara生物医药 ATRA 深 沪
等待开盘 12-19 09:30:00 美东时间
17.23
+0.050
+0.29%
华盛通- 最 高17.80
- 今 开17.22
- 成交量 3.64万股
- 最 低 17.12
- 昨 收 17.18
- 总市值 1.24亿
- 52周最高 18.705
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.005
- 委 比 89.47%
- 总股本 721.02万
- 历史最高 1639.00
- 量 比 0.46
- 振 幅 3.96%
- 历史最低 4.965
- 每 手 1
- 风险率 3.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.86) by 62.79 percent. This is a 89.08 percent increase over losses of $(2.93) per share
11-12 22:06
Pierre Fabre Pharmaceuticals Takes Over Tabelecleucel BLA From Atara Biotherapeutics Ahead Of FDA Priority Review On January 10, 2026 For First U.S. EBV+ PTLD Therapy
Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDUFA) target action
11-03 22:18
Immatics Appoints Amie Krause as Chief People Officer
Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ...
10-27 19:00
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
09-29 19:11
Atara Biotherapeutics' Greg Ciongoli To Assume The Role Of Chair Of The Board Of Directors
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
09-04 06:03
Yatra Online Limited Relocates Registered Office
Yatra Online Limited ( ($IN:YATRA) ) has issued an update. Yatra Online Limited...
08-28 03:03
Atara Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Atara Biotherapeutics shares are trading higher after the company reported bett...
08-12 22:33
Atara Biotherapeutics Q2 EPS $0.19 Beats $(0.81) Estimate, Sales $17.57M Beat $5.67M Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $(0.81) by 123.54 percent. This is a 106.13 percent increase over losses of $(3.10) per
08-12 04:13
生产经营｜绿色船舶+1 广船国际交付4.95万吨甲醇双燃料油轮
7月22日，中船集团广船国际联合中船贸易为丹麦HAFNIA和法国SOCATRA创立的合资公司ECOMAR建造的4.95万吨甲醇双燃料油轮3号船“ECOMAR ...
07-25 17:16
Atara Biotherapeutics Says FDA Accepts Filing Of BLA For Tabelecleucel Indicated As Monotherapy For Treatment Of Patients With EBV+ PTLD Who Have Received At Least One Prior Therapy
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLDAtara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell
07-24 20:20
